AMGN vs BIIB · P/E 24, rev $10.05B vs P/E 21, rev $9.89B
Amgen Inc (AMGN) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the AMGN and BIIB stock pages for the full models.
Not investment advice.